Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today ...

As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

Deutsche Bank analyst Falko Friedrichs maintained a Sell rating on Evotec (0IRF – Research Report) today and set a price target of €4.00. The company’s shares closed last Friday at €8.60. Don't Miss ...

Halozyme Therapeutics, a San Diego-based biopharmaceutical company, has made a $2.1 billion bid to buy German drugmaker ...

The local company announced Friday morning at 5:35 a.m. that it was withdrawing its bid to buy Evotec for about $11.52 per ...

Halozyme Therapeutics (HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, ...

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024 ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

Halozyme Therapeutics said Friday that it has pulled its proposal to buy Evotec, a struggling German biotech that Halozyme said was ...

Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...

Halozyme Therapeutics (HALO) stock gains as company withdraws proposal to acquire Evotec SE (EVO), citing latter's reluctance ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...